TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07266831: A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Co

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2/PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 570 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,269,960

Rescue Site Savings

+$6,776,490

Unlock Full NCT07266831 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07266831 Rescue Dossier →